Evaluation of Intravenous Cardene(Nicardipine)and Labetalol Use in the Emergency Department

Part of paid clinical trials in Cleveland, Ohio.

Sponsor
The Cleveland Clinic
Study ID
NCT00765648
Phase
PHASE4
Status
Completed

Conditions

  • Hypertensive Urgency

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • nicardipine intravenous — DRUG
    nicardipine intravenous 5 mg/hour titrated every 5 minutes by 2.5 mg/hour until target systolic blood pressure range (TSBPR) is reached or maximum dose of 15 mg/hour is achieved.Following achievement of target systolic blood pressure range the infusion rate should be decreased to 3 mg/hour
  • Labetalol — DRUG
    Labetalol: bolus therapy to start at 20 mg intravenous injection over 2 minutes, may repeat 20mg, 40mg or 80mg injections every 10 minutes until target systolic blood pressure range(TSBPR)is reached or a maximum of 300 mg is injected.

Study Details

The purpose of this study is to compare the safety and efficacy of Cardene I.V. to labetalol administered intravenously for the management of hypertension in the emergency department setting.

Key Dates

Start date
Oct 31, 2008
Status verified
Jul 2011
Primary completion
Jan 31, 2010
Completion
Jan 31, 2010

Study Design

Enrollment
226 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: 1
    nicardipine intravenous
  • Active Comparator: 2
    Labetalol

Primary Outcome Measure

Percentage of Subjects Achieving a Pre-defined Target Systolic Blood Pressure (BP) Within 30 Minutes. [ Time Frame: 30 minutes after initiation of therapy ]

Locations (2)

FacilityCityStateZIPSite coordinators
Cleveland ClinicClevelandOhio44122-
University of Texas Health Science CenterHoustonTexas--

Find similar trials in Cleveland, OH

By research site
Cleveland Clinic· Cleveland, OHUniversity of Texas Health Science Center· Houston, TX

Related Studies